Manuel Litchman

765 total citations
11 papers, 544 citations indexed

About

Manuel Litchman is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Manuel Litchman has authored 11 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Hematology and 2 papers in Molecular Biology. Recurrent topics in Manuel Litchman's work include Drug Transport and Resistance Mechanisms (8 papers), Acute Myeloid Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). Manuel Litchman is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Acute Myeloid Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). Manuel Litchman collaborates with scholars based in United States, Switzerland and Italy. Manuel Litchman's co-authors include Branimir I. Šikić, Ranjana H. Advani, Peter H. Wiernik, Elisabeth Paietta, Jacob M. Rowe, Eric Davis, Peter L. Greenberg, Kathleen Dugan, Martin S. Tallman and Bert L. Lum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Manuel Litchman

11 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manuel Litchman United States 10 435 189 147 140 65 11 544
Greta Cipriani Italy 7 325 0.7× 166 0.9× 114 0.8× 91 0.7× 32 0.5× 7 529
M. Schoester Netherlands 15 464 1.1× 368 1.9× 140 1.0× 303 2.2× 87 1.3× 23 752
Robert Oostrum Netherlands 7 422 1.0× 310 1.6× 98 0.7× 60 0.4× 48 0.7× 9 610
Zineb Benderra France 7 290 0.7× 193 1.0× 66 0.4× 85 0.6× 22 0.3× 7 374
Olga Ujhelly Hungary 10 514 1.2× 400 2.1× 113 0.8× 95 0.7× 28 0.4× 15 759
B Jachez France 9 409 0.9× 223 1.2× 134 0.9× 37 0.3× 26 0.4× 15 533
Joanna Regis United States 10 550 1.3× 270 1.4× 160 1.1× 26 0.2× 35 0.5× 14 660
Marie Stupecky United States 8 435 1.0× 326 1.7× 93 0.6× 30 0.2× 34 0.5× 10 562
Maria A.J. van Eijndhoven Netherlands 7 356 0.8× 258 1.4× 77 0.5× 26 0.2× 25 0.4× 8 520
Sabine Plasschaert Netherlands 9 207 0.5× 181 1.0× 116 0.8× 52 0.4× 124 1.9× 25 431

Countries citing papers authored by Manuel Litchman

Since Specialization
Citations

This map shows the geographic impact of Manuel Litchman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Litchman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Litchman more than expected).

Fields of papers citing papers by Manuel Litchman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Litchman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Litchman. The network helps show where Manuel Litchman may publish in the future.

Co-authorship network of co-authors of Manuel Litchman

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Litchman. A scholar is included among the top collaborators of Manuel Litchman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Litchman. Manuel Litchman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Porter, David L., Simon F. Lacey, Wei‐Ting Hwang, et al.. (2014). Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. Blood. 124(21). 1983–1983. 6 indexed citations
2.
3.
Porter, David L., Michael Kalos, Norbert Frey, et al.. (2013). Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. Blood. 122(21). 873–873. 17 indexed citations
4.
Advani, Ranjana H., George A. Fisher, B L Lum, et al.. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.. PubMed. 7(5). 1221–9. 62 indexed citations
5.
Visani, Giuseppe, D W Milligan, Fabiana Leoni, et al.. (2001). Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia. 15(5). 764–771. 25 indexed citations
6.
Dorr, R T, Chatchada Karanes, Catherine Spier, et al.. (2001). Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology. 19(6). 1589–1599. 65 indexed citations
7.
Fracasso, Paula M., David Rosen, Eleanor G. Zuhowski, et al.. (2000). Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies. Journal of Clinical Oncology. 18(5). 1124–1124. 66 indexed citations
8.
Patnaik, Amita, Ellen Warner, Michael Michael, et al.. (2000). Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 18(21). 3677–3689. 17 indexed citations
9.
Advani, Ranjana H., Giuseppe Visani, D Milligan, et al.. (1999). Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC). Advances in experimental medicine and biology. 457. 47–56. 33 indexed citations
10.
Advani, Ranjana H., Hussain I. Saba, Martin S. Tallman, et al.. (1999). Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). Blood. 93(3). 787–795. 109 indexed citations
11.
Advani, Ranjana H., Hussain I. Saba, Martin S. Tallman, et al.. (1999). Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). Blood. 93(3). 787–795. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Greta Cipriani Breakdown of academic impact, for papers by M. Schoester Breakdown of academic impact, for papers by Robert Oostrum Breakdown of academic impact, for papers by Zineb Benderra Breakdown of academic impact, for papers by Olga Ujhelly Breakdown of academic impact, for papers by B Jachez Breakdown of academic impact, for papers by Joanna Regis Breakdown of academic impact, for papers by Marie Stupecky Breakdown of academic impact, for papers by Maria A.J. van Eijndhoven Breakdown of academic impact, for papers by Sabine Plasschaert
Rankless by CCL
2026